Cellmid selects lead antibody for clinical trials

/in /by

THE ROADHOUSE PHARMACY: Cellmid Limited (ASX: CDY) has completed
humanisation, testing and selection of its lead anti-midkine (MK)
antibody for the company’s planned ‘first in class’ clinical trials in
oncology.

The company said this was a major step in advancing towards clinical studies and keeps it on track with the development program outlined to the market earlier in 2014.

Cellmid claims the lead antibody, designated CAB102, has been shown to greatly reduce chemotherapy resistance in a preclinical model of lung cancer in combination with carboplatin.

In addition to its functional activity in vivo, it has produced strong in vitro functionality in specifically designed MK migration assays.

Initial cell expression and stability data has confirmed it can be manufactured commercially, making it a feasible drug product.

“With the completion of lead selection, and after a well-planned and extensive testing program, our preparations for clinical trials are well on track,” Cellmid chief executive officer Maria Halasz said in the company’s announcement to the Australian Securities Exchange.

Website: www.cellmid.com.au